Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimicrobial update.

R A Prince

    Drug Intelligence & Clinical Pharmacy
    |July 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    This review compares new and existing antimicrobial drugs, including amdinocillin and quinolones, to identify potential therapeutic and cost benefits for clinical use.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

    Antimicrobial agents and chemotherapy·2007
    Same author

    Chest radiograph heterogeneity predicts functional improvement with volume reduction surgery.

    The Annals of thoracic surgery·2000
    Same author

    Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

    Antimicrobial agents and chemotherapy·2000
    Same author

    Effect of a dual-lumen peripheral catheter on the delivery of known incompatible medications.

    The Annals of pharmacotherapy·1998
    Same author

    A peroxisome proliferator-activated receptor-alpha (PPARalpha) cDNA cloned from guinea-pig liver encodes a protein with similar properties to the mouse PPARalpha: implications for species differences in responses to peroxisome proliferators.

    Archives of toxicology·1998
    Same author

    A simple method for administering vancomycin in the spinal cord injured population.

    Archives of physical medicine and rehabilitation·1997
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Area of Science:

    • Pharmacology and Infectious Diseases

    Background:

    • Antimicrobial resistance necessitates continuous development of new therapeutic agents.
    • Evaluating the clinical and economic profiles of novel antimicrobials is crucial for optimizing treatment strategies.

    Purpose of the Study:

    • To review and compare newly available and upcoming antimicrobial drugs against established agents.
    • To assess potential therapeutic and cost advantages offered by these new antimicrobials.

    Main Methods:

    • Literature review and comparative analysis of antimicrobial agents.
    • Inclusion of drugs such as amdinocillin, ticarcillin/clavulanic acid, ceftriaxone, ceftazidime, imipenem/cilastatin, aztreonam, and quinolones.

    Main Results:

    • Identification of specific drugs with potential advantages in efficacy or cost-effectiveness.

    Related Experiment Videos

  • Comparative data presented for key antimicrobial classes.
  • Conclusions:

    • New antimicrobial agents offer promising therapeutic and economic benefits.
    • Informed selection of antimicrobials can improve patient outcomes and healthcare economics.